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LETTERS TO THE EDITOR
Update From the Thrombolysis in
Myocardial Infarction Trial
In February 1987 the TIMI Operations Committee reported
on protocol changes in the Thrombolysis in Myocardial
Infarction Trial (1). The changes were a reduction in the
dose of recombinant tissue plasminogen activator (rt-PA)
from 150 mg given over 6 hours to 100 mg given over 6
hours, and the exclusion criteria, such as history of
hypertension and history of neurologic disease, were made
more stringent. Since that protocolchange, more than 1,300
patients have been treated with the lower dose, and the
occurrence of majorhemorrhagicevents, includingintracranial
hemorrhages, has been substantially reduced. Preliminary
results of the experience with 100 mg as of June 24, 1987
are given in Table I. As indicated, pooling the results for
all TIMI paiients treated with 100 mg was associated with
intracranial hemorrhage in 0.6% of patients compared with
1.6% for all patients treated with 150 mg. Thrombolytic
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therapy should be given to individuals only after careful
screening for contraindications suchas priorneurologic events,
severe hypertension and potential bleeding sites.
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Table 1. TIMI Experience With Suspension Culture rt-PA in 2,466 Patients: Preliminary Findings for Intracranial Hemorrhage
Recru itment No .
T1MI Study Period rt-PA Dose Treated
Open label A 8/5/85 to 9/24/85 80 mg over 3 hours (40. 20 , :20 per h) 48
Open label B 9/ 17/85 to 12/26/85 100 mg over 3 hours (60 with initial 6 88
mg bolus, 20 , 20 per h)
Open label C 12/9/85 to 2/ 12/86 150 mg over 6 hours (90 with initia l 9 65
mg bolus. 20. 10 . 10, 10 , \0 per h)
Open label D 2/8/86 to 3/16/86 150 mg over 6 hours (90 with initial 9 42
mg bolus. 20. 10. \0. 10. 10 per h)
Open label E 3/ 17/86 to 10/20/86 150 mg over 6 hours (90 with initial 9 326
mg bolus. 20. 10. 10, 10, 10 per h)
Phase II 4/ \1 /86 to \0/20/86 \50 mg ove r 6 hou rs (90 with initial 9 58 1
mg bolus. 20, 10, 10, 10. 10 per h)
Open label E 10/2 1/86 to 1/19/87 \00 mg over 6 hours (60 with initial 6 53
mg bolus, 20 , 5. 5 . 5, 5 per h)
Phase 1\ 1012\ /86 to 6/24/87 100 mg over 6 hours (60 with initial 6 1.311
mg bolus, 20. 5. 5, 5. 5 per h)
Open label C. D. E: 150 mg over 6 hours 1.0 14
Phase II
Open label B. E: 100 mg over 6 hours 1.452
Phase 1I
Intracran ial hemorrh age
No. %
°
0 .0
I 1. 1
a 0 .0
a 0. 0
5 1.5
\1 1.9
a 0 .0
7 0.5
16 1.6
8 0 .6
Co mparison of all experience for patients given 150 mg versus 100 mg by X! test yie lded p = 0.01. rt-PA = recombinant tissue plasminogen
activator.
